Page 21 - Codebase Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Codebase Ventures Inc.: Codebase Receives Positive Technical Study Results for HCQ Transdermal Patch Technology Viability to Address Underserved Lupus, Rheumatoid Arthritis and Malaria market, forecast to be worth $6 Billion USD by 2027 , Company to investigate Spin Out of Asset VANCOUVER, BC / ACCESSWIRE / April 1, 2021 / Codebase Ventures Inc. ( Codebase or the Company ) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is pleased to provide an update on the continued development of the Company s proposed transdermal delivery technology for hydroxychloroquine (HCQ), as first announced in April 2020. The Company engaged TRPL (Transdermal Research Pharm Laboratories) of Long Island City of New York, to conduct a feasibility study which indicates that HCQ has all the required parameters to be a transdermal candidate.

British columbiaGeorge tsafalasIvy luGlanis pharmaceuticals incNeither the canadian securities exchangeCodebase ventures incCanadian securities exchangeRegulation services providerAddress underserved lupusRheumatoid arthritisSpin outCodebase venturesTransdermal research pharm laboratoriesLong island cityNew yorkபிரிட்டிஷ் கொலம்பியா